Plexin B2 Gene Expression and Polymorphisms in Psoriasis
Psoriasis Vulgaris
About this trial
This is an interventional treatment trial for Psoriasis Vulgaris
Eligibility Criteria
Inclusion Criteria:
- Patients of both sexes. Diagnosed clinically with moderate to severe Psoriasis Vulgaris.
- patients able to swallow tablet and receive Narrow band Ultraviolet B phototherapy without any contraindication
Exclusion Criteria:
Pregnancy , lactation & women intent to become pregnant within 3 year after discontinuation of acitretin Patients with Hyperlipidemia Patients with mental problems and depression Patients with a history of malignancies, renal & liver diseases. Patients with a history of any inflammatory diseases as atopic dermatitis , asthma ulcerative colitis ) and Crohn's disease Patients received NB-UVB phototherapy in the last 6 months. Patients treated with methotrexate or biologic agents and any systemic treatment of psoriasis.
Sites / Locations
- Faculty of Medicine , South Valley University
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Active Comparator
Active Comparator
Active Comparator
No Intervention
Narrow band Ultraviolet B phototherapy group
Acitretin group
Acitretin plus Narrow band Ultraviolet B phototherapy group
Control group
Patients will be treated with Narrow band Ultraviolet B phototherapy 3 sessions weekly for 3 months with maximum dose of 1400 mJ/cm2.
Patients will be treated with Acitretin in dose of 0.5-1 mg per kg per day orally for 3 months
Patients will be treated with Acitretin in dose of 0.5-1 mg per kg per day orally plus NB-UVB phototherapy 3 sessions weekly for 3 months with maximum dose 1400 mJ/cm2.
30 healthy individuals un related , age, sex , BMI matched with volunteers.